Home » Stocks » Dyne Therapeutics

Dyne Therapeutics, Inc. (DYN)

Stock Price: $22.60 USD -1.30 (-5.44%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
After-hours: $22.25 -0.35 (-1.55%) Sep 18, 7:46 PM

Stock Price Chart

Key Info

Market Cap 985.03M
Revenue (ttm) n/a
Net Income (ttm) -28.14M
Shares Out 43.59M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $22.60
Previous Close $23.90
Change ($) -1.30
Change (%) -5.44%
Day's Open 22.20
Day's Range 22.00 - 23.50
Day's Volume 472,214
52-Week Range 22.00 - 27.11

More Stats

Market Cap 985.03M
Enterprise Value 983.30M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 43.59M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.68
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -28.14M
Free Cash Flow n/a
Net Cash 1.72M
Net Cash / Share 0.04
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-13.83-4.80
Net Income-14.86-4.81
Shares Outstanding2.440.47
Earnings Per Share-6.08-10.15
Operating Cash Flow-11.83-4.16
Capital Expenditures-1.65-0.13
Free Cash Flow-13.48-4.30
Cash & Equivalents14.638.12
Net Cash / Debt14.638.12
Book Value14.04-4.88
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Dyne Therapeutics, Inc.
Country United States
Employees 2,489
CEO Joshua T. Brumm

Stock Information

Ticker Symbol DYN
Stock Exchange NASDAQ
Sector Other
Industry Other
Unique Identifier NASDAQ: DYN
IPO Date September 17, 2020


Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.